共 265 条
[71]
Stallmach A(2016)Efficacy of vedolizumab as induction therapy in refractory IBD patients following multiple anti-TNF therapy failures Acta Clinica Belgica 71 S7-undefined
[72]
Langbein C(2016)Efficacy of vedolizumab as induction therapy for inflammatory bowel disease in a ‘real-life’ study Am J Gastroenterol 111 S270-undefined
[73]
Atreya R(2016)Efficacy and safety of vedolizumab in patients with inflammatory bowel disease in a large tertiary medical center J Crohns Colitis. 10 S214-undefined
[74]
Ungar B(2012)Hospitalisations and characteristics of patients with ulcerative colitis and Crohn’s disease treated with vedolizumab in real-world clinical practice: results from a multicentre study Digestion. 86 11-undefined
[75]
Kopylov U(2017)Therapy of steroid-resistant inflammatory bowel disease Inflamm Bowel Dis 23 97-undefined
[76]
Waterman M(2017)Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy Inflamm Bowel Dis 23 S25-undefined
[77]
Vivio EE(2016)A retrospective United Kingdom chart review of early vedolizumab experience: real-world treatment, effectiveness and safety in inflammatory bowel disease (REVIVE) J Crohns Colitis. 10 S173-undefined
[78]
Kanuri N(2013)Real-world treatment persistence with vedolizumab in Crohn’s disease and ulcerative colitis patients Gut 62 630-undefined
[79]
Gilbertsen JJ(2016)Geographical variability and environmental risk factors in inflammatory bowel disease Expert Rev Gastroenterol Hepatol 10 915-undefined
[80]
Wright AP(2011)Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease Gastroenterology 141 1194-undefined